Register Login

All Posts

Nov 24 2025
george

11-8-25 AHA Presentation Records Successful Reduction of Anticoagulation in AFIB

Click here for the results of a “One month of clot prevention after a stent was as effective as a Year-long course for AFIB.” Research Highlights: A one-month course of dual clot-preventing therapy followed by a single clot-prevention medication for the remainder of the standard 12-month regimen in adults with atrial fibrillation (AFib) who received […]
read more
Comments (0)
Anticoagulant Therapy
Nov 19 2025
george

An Illustrated Review of Hemophilia B.

Click here for the illustrated open-access review, Hermans C, Astermark J, Trakymienė SŠ, Jiménez-Yuste, V. Haemophilia B: an illustrative review of current challenges and opportunities.  Res Prac Thromb Haemostasis, 2025;9, 103229. Abstract Background Hemophilia B is a genetic bleeding disorder caused by a deficiency of clotting factor IX, which presents unique challenges in clinical management. […]
read more
Comments (0)
Bleeding Disorders
Nov 19 2025
george

VWF Factor Assays in Caplacizumab Therapy

Check with your medical library or join ISTH to obtain Colpani P, Baronciani L, Mancini I, et al. Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor-platelet interaction. J Thromb Haemost. 2025:S1538-7836(25)00545-8. doi: 10.1016/j.jtha.2025.08.020. PMID: 40915571. Abstract Background: Caplacizumab, a humanized […]
read more
Comments (0)
Bleeding Disorders
Nov 19 2025
george

Viewpoint: Anticoagulation for Climate Resilient Care

Go to your medical library to obtain Fan BE, Milla K, McAlister S, et al, Sustainable anticoagulation for climate resilient care. Lancet Haematol. 2025;12:e918-e925. doi: 10.1016/S2352-3026(25)00204-2.  PMID: 40972616. Abstract This Viewpoint issues a multidisciplinary call to embed sustainability into anticoagulation care, aligning clinical excellence with climate responsibility. Anticoagulation management-including drug manufacturing, laboratory diagnostics, therapeutic monitoring, […]
read more
Comments (0)
Anticoagulant Therapy
Load more

George Fritsma MS MLS

George Fritsma is a medical laboratory scientist, educator, and author. George  is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

read more

Cheat Sheets from George

Name

Questions or Comments?

Email George

Quick Question

What VWD therapeutic is NOT a replacement factor?